Professional Documents
Culture Documents
SpO2 trend
FiO2 trend
®
OxyGenie : Reducing your Workload ®
automated 91-95%) T
16
14
12 T
10
8 T
6
4
2
0
<80 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100
SpO2 (%)
Graph (above) shows percentage of time SpO2 is in range - comparing manual control with OxyGenie. [3]
70 70
Frequency (number per 4 hours)
Eupoxia (% time)
50 50
40 40 10 10
30 30
20 20 5 5
10 10
0 0 0 0
Eupoxia Eupoxia 30 s 30 s 60 s 60 s 30 s 30 s 60 s 60 s
Eupoxia time (time inEupoxia
target time (time in target Hypoxaemic episodes
Hypoxaemic episodes Hyperoxaemic episodes
Hyperoxaemic episodes
range or above target range or above target range
range
when in room air) when in room air)
SpO2 < 85% SpO2 < 85% SpO2 > 96% in SpO
oxygen
2
> 96% in oxygen
Graph 1 (left): shows OxyGenie-treated babies spend more time in Eupoxia. (Time in target range or above target range when in room air).
Note, there is no overlap in distribution.
Graph 2 (right): shows OxyGenie significantly reduces the number, duration and severity of hypoxaemic/hyperoxaemic episodes, and virtually
eliminates severe episodes of 60 s or more [3].
®
SLE6000: Ventilate with Confidence
SLE6000 Integration
Various software and hardware modules
can be added to the SLE6000 during
production or at a later date as an HFOV (VTV) nHFOV
HFOV+CMV
upgrade.
References 5
Clarke, A., Yeomans, E., Elsayed, K.,
1
Saugstad OD, Aune D.
Medhurst, A., Berger, P., Skuza, E. and Tan,
Optimal oxygenation of extremely low birth
K. (2015)
weight infants: a meta-analysis and systematic
review of the oxygen saturation target studies. A randomised crossover trial of clinical
Neonatology 2014;105:55–63. algorithm for oxygen saturation targeting in
preterm infants with frequent desaturation
2
Poets CF, Roberts RS, Schmidt B, et al. episodes.
Association between intermittent hypoxemia
Neonatology, 107 (2), 130-136.
or bradycardia and late death or disability in
extremely preterm infants.
JAMA 2015;314:595–603.
3
Plottier GK, Wheeler KI, Ali SKM, Sadeghi
Fathabadi O, Jayakar R, Gale TJ, Dargaville
PA.
Clinical evaluation of a novel adaptive algorithm
for automated control of oxygen therapy in
preterm infants on non-invasive respiratory
support.
Arch Dis Child Fetal Neonatal Ed 2017; 102:
F37-F43.
4
Peter A Dargaville, Omid Sadeghi
Fathabadi, Gemma K Plottier, Kathleen Lim,
Kevin I Wheeler, Rohan Jayakar, Timothy J
Gale
Development and preclinical testing of an
adaptive algorithm for automated control of
inspired oxygen in the preterm infant
Arch Dis Child Fetal Neonatal Ed 2016;0:F1–F6.
Specifications and Part numbers
Specifications
Item Description
Main software Software control system that allows targeting of SpO2 values by
controlling FiO2. Correlate SpO2 and FiO2 trends
Works in conjunction with Masimo™ software module and Masimo™
sensors to monitor SpO2 values (bought separately)
Controls Adds additional (start/stop) option to FiO2 parameter controller.
Range selector in SpO2 utilities menu. Ranges are: 90 - 94%,
91 - 95% (default), 92 - 96%, 94 - 98%
Manual override (timed, for 30 seconds)
Waveforms Additional SpO2 screen can show any one ventilation parameter plus
plethysmogram and trends of SpO2 and FiO2.
Alarms Alarms automatically set on SpO2 software, corresponding with target
range (1% above high and 1% below low). These can be manually set
as well.
Alarm indications shown in Alarm bar.
Alarm level indicators on SpO2 and FiO2 graphs. Large status indicator
Indicator Status panel (in bottom right-hand corner) shows OxyGenie status
such as ‘Auto’, ‘Manual Override’ (with countdown) or ‘Waiting for
Signal’.
Trends Trending information for SpO2 and FiO2 can be shown simultaneously.
Up to 14 days of data are stored for each parameter.
sales@sle.co.uk
South Croydon
www.sle.co.uk
SLE Limited
CR2 6PL
Surrey
UK
Masimo, SET and are federally registered trademarks of Masimo Corporation.
OxyGenie® is a registered trade mark of SLE Ltd in the EU. | SLE and SLE6000 are trademarks of SLE Ltd.
All other names, logos, and brands are property of their respective owners. | Copyright SLE Ltd ©2018 | Subject to Change | G0159/0UK/001 04/19